Fact Sheet
EU HTA Regulation: All set for 2025?
Jan 23, 2025
Download
Starting in 2025, the HTA clinical assessment of new cancer drugs and Advanced Therapy Medicinal Products (ATMPs) will be conducted centrally. These Joint Clinical Assessments (JCAs) are aiming to streamline HTA efforts across EU Member States and ultimately accelerating patient access to innovative medicines. Read this factsheet to understand what clients should do to be prepared for the new market access pathway in Europe.

Related solutions

Contact Us